Summary
We have studied the pharmacokinetics of enoxacin in two groups of subjects, 10 young (18–45 years) and 10 elderly adults (>65 years) after a single oral dose of enoxacin (600 mg).
Enoxacin was absorbed rapidly, peak plasma concentrations being reached within two hours in both groups. However, the peak plasma concentration of enoxacin was significantly higher in the elderly than in the young adults.
The area under the concentration-time curve extrapolated to infinity was also significantly greater in the elderly compared with the young subjects, and the apparent renal clearance was significantly less in the elderly than in the young adults. Consequently, the urinary elimination of unchanged enoxacin was significantly reduced in the elderly.
The apparent volume of distribution in the elderly was significantly less than in the young adults. The elimination half-time of enoxacin was similar in the two groups.
This is a preview of subscription content, log in via an institution to check access.
References
Bailey RR, Peddie BA (1985) Enoxacin for the treatment of urinary tract infection. NZ Med J 98: 286–288
Barry AL, Jones RN (1984) Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after invitro selection of resistant strains. Antimicrob Agents Chemother 25: 775–777
Bassey CM, Baltch AL, Smith RP, Conley PE (1984) Comparative in vitro activities of enoxacin (CI-919, AT-2266) and eleven antipseudomonal agents against aminoglycoside-susceptible and -resistant pseudomonas aeruginosa strains. Antimicrob Agents Chemother 26: 417–418
Bjornsson TD, Cochetto DM, McGowan FX, Verghese CP, Sedor F (1983) Nomogram for estimating creatinine clearance. Clin Pharmacokinet 8: 365–369
Carlson JR, Thornton SA, DuPont HL, West AH, Mathewson JJ (1983) Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens. Antimicrob Agents Chemother 24: 509–513
Ho P, Triggs EJ (1984) Drug therapy in the elderly. Aust NZ J Med 14: 179–190
Perrier D, Gibaldi M (1982) Pharmacokinetics, vol. II. Marcel Decker, New York, pp 409–417
Rinetti M, Cerutti R, Cisternino M, Colombi-Zinelli L (1984) Pharmacokinetics in the elderly. Int J Clin Pharmacol Res 4: 425–429
Rudrik JT, Cavalieri SJ, Britt EM (1984) In vitro activities of enoxacin and 17 other antimicrobial agents against multiply resistant, gram-negative bacteria. Antimicrob Agents Chemother 26: 97–100
Schmucker DL (1985) Aging and drug disposition — an update. Pharmacol Revs 37: 133–148
Selwyn S, Bakhtiar M (1984) Comparative in vitro studies on a new azaquinolone, enoxacin. Drugs Exp Clin Res 10: 653–668
Thomas MG, Ellis-Pegler RB (1985) Enoxacin treatment of urinary tract infections. J Antimicrob Chemother 15: 759–764
Wilcoxon F (1945) Individual comparisons by ranking methods. Biometric Bull 1: 80–83
Wise R, Andrews JM, Danks G (1984) In-vitro activity of enoxacin (CI-919), a new quinolone derivative compared with that of other antimicrobial agents. J Antimicrob Chemother 13: 237–244
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dobbs, B.R., Gazeley, L.R., Campbell, A.J. et al. The effect of age on the pharmacokinetics of enoxacin. Eur J Clin Pharmacol 33, 101–104 (1987). https://doi.org/10.1007/BF00610390
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00610390